1.
JAAPA
; 32(3): 16-18, 2019 Mar.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30817475
RESUMEN
The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy.